| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514362000 | 1,2,5-thiadiazoles (including hydrogenated) | 20 |
| 20080207703 | Antibacterial heterocyclic ureas - The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same. | 08-28-2008 |
| 20080214629 | CONTROLLED RELEASE COMPOSITIONS OF TIZANIDINE - The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient. | 09-04-2008 |
| 20080262050 | Organic Compounds - Compounds of the formula | 10-23-2008 |
| 20080293782 | 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors - Compounds of the formula | 11-27-2008 |
| 20090062354 | Method of increasing the extent of absorption of tizanidine - An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 03-05-2009 |
| 20090170911 | NOVEL AZOLE COMPOUND - Azole compounds represented by formula I: | 07-02-2009 |
| 20100035942 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors - Compounds of the formula | 02-11-2010 |
| 20100130566 | Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus - Noradrenergic system - Methods are provided for treating autism spectrum disorders (ASD) using agents that activate the locus coeruleus-noradrenergic (LC-NA) system of the brain and for screening for compounds for treating ASD comprising determining whether or not the compounds activate the LC-NA system. | 05-27-2010 |
| 20110092554 | 1,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS - The present disclosure relates to novel 1,3,5 tri-substituted benzenes of general formula (I), (II) or (III) and the use of such compounds in the treatment of diseases associated with the deposition of -amyloid in the brain. | 04-21-2011 |
| 20110160253 | DEUTERATED TIZANIDINE - This disclosure relates to novel benzothiadiazoles, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α | 06-30-2011 |
| 20110269804 | INSECTICIDAL COMPOUNDS - A compound of formula (I): | 11-03-2011 |
| 20120108643 | METHOD OF INCREASING THE EXTENT OF ABSORPTION OF TIZANIDINE - An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 05-03-2012 |
| 20120196906 | Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors - The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes. | 08-02-2012 |
| 20130165486 | TETRASUBSTITUTED BENZENES - Tetrasubstituted benzenes that act as modulators of gamma secretase and their use in the treatment of one or more symptoms of treating neurodegenerative disorders, e.g., Alzheimer's disease, are described. | 06-27-2013 |
| 20130210869 | METHOD OF INCREASING THE EXTENT OF ABSORPTION OF TIZANIDINE - An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 08-15-2013 |
| 20130338200 | PHARMACEUTICAL DOSAGE FORMS OF TIZANIDINE AND ADMINISTRATION ROUTES THEREOF - A pharmaceutical composition in liquid dosage form which contains a tizanidine hydrocloride aqueous solution suitable for parenteral, intranasal and oral administration. | 12-19-2013 |
| 20150038539 | METHOD OF INCREASING THE EXTENT OF ABSORPTION OF TIZANIDINE - An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution. | 02-05-2015 |
| 20150141473 | PHARMACEUTICAL DOSAGE FORMS OF TIZANIDINE AND ADMINISTRATION ROUTES THEREOF - A pharmaceutical composition in liquid dosage form which contains a tizanidine hydrocloride aqueous solution suitable for parenteral, intranasal and oral administration. | 05-21-2015 |
| 20160031839 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. | 02-04-2016 |
| 20160200697 | INHIBITION OF WNT, TGF BETA AND HIPPO SIGNALING PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | 07-14-2016 |
